➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 6,916,787

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,916,787
Title: Method for producing hemin proteins using plant cells, resulting proteins and products containing same
Abstract:A method for producing haemin proteins by (i) inserting into plant cells one or more nucleic acid molecules that each comprise at least one sequence coding for a protein component of an animal haemin protein capable of reversibly binding oxygen, or for a variant or portion of said protein component, and optionally a sequence coding for a selection agent; (ii) selecting cells containing nucleic acid coding for the protein component of the haemin protein; (iii) optionally propagating the transformed cells either in a culture or by regenerating whole transgenic or chimeric plants; and (iv) recovering and optionally purifying a haemin protein that includes a complex consisting of the protein or proteins coded for by said nucleic acid and at least one iron-containing porphyritic nucleus, or a plurality of such complexes.
Inventor(s): Merot; Bertrand (Volvic, FR), Dieryck; Wilfrid (Saint-Pathus, FR), Lenee; Philippe (Noumea, FR), Marden; Michael (Aulnay-sous-Bois, FR), Gruber; Veronique (Chamalieres, FR), Pagnier; Renee-Josee (Le Kremlin-Bicetre, FR), Baudino; Sylvie (Orcines, FR), Poyart; Claude (Paris, FR)
Assignee: Institut National de la Sante et de Recherche Medicale (Paris Cedex, FR) Meristern Therapeutics (Clermont-Ferrand, FR)
Application Number:10/085,853
Patent Claims:see list of patent claims

Details for Patent 6,916,787

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial Institut National de la Sante et de Recherche Medicale (Paris Cedex, FR) Meristern Therapeutics (Clermont-Ferrand, FR) 2015-07-17 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.